Manchester Peptides catalogue profile
Eloralintide
Coming soon in 10 mg pen and vial formats. Eloralintide (LY3841136) is an investigational selective amylin-receptor agonist studied for appetite, satiety and body-weight regulation. Phase 1 and Phase 2 studies have been completed, and Phase 3 trials are ongoing. Research information only; this listing does not establish approval or equivalence to clinical-trial material.
Coming-soon formats
Eloralintide 10 mg · Pens & vials
Coming soon. Release date and prices to be confirmed; ordering is not open.Pen · 10 mg
Coming soonEloralintide
Product information
Coming soon in 10 mg pen and vial formats. Eloralintide (LY3841136) is an investigational selective amylin-receptor agonist studied for appetite, satiety and body-weight regulation. Phase 1 and Phase 2 studies have been completed, and Phase 3 trials are ongoing. Research information only; this listing does not establish approval or equivalence to clinical-trial material.
Lilly: Eloralintide mechanism and clinical developmentFor research and reference purposes only. Listing a product does not establish suitability for medical use.
Vial · 10 mg
Coming soonEloralintide
Product information
Coming soon in 10 mg pen and vial formats. Eloralintide (LY3841136) is an investigational selective amylin-receptor agonist studied for appetite, satiety and body-weight regulation. Phase 1 and Phase 2 studies have been completed, and Phase 3 trials are ongoing. Research information only; this listing does not establish approval or equivalence to clinical-trial material.
Lilly: Eloralintide mechanism and clinical developmentFor research and reference purposes only. Listing a product does not establish suitability for medical use.EloralintideView information poster+
Eloralintide information poster
A visual reference for amylin receptor research, appetite signalling and the eloralintide development programme.
- Amylin receptor activity
- Appetite signalling research
- Clinical development
This visual summary is a starting point. The linked research guide provides sources, evidence levels and limitations.
Research update · 28 October 2026
What does Eloralintide do?
Eloralintide (LY3841136) is an investigational selective amylin-receptor agonist developed by Lilly. It is designed to act on the AMY1 receptor, a pathway involved in fullness and food intake. Researchers are studying whether this can reduce appetite and body weight. Its primary target differs from the GLP-1/GIP pathways targeted by tirzepatide.
What did the Phase 2 study find?
A 48-week, placebo-controlled study enrolled 263 adults with obesity, or overweight with a related condition, without type 2 diabetes. Mean weight reduction across the eloralintide groups ranged from 9.5% to 20.1%, compared with 0.4% for placebo, using the efficacy estimand. That analysis estimates outcomes if participants remained on treatment. Common adverse events included gastrointestinal symptoms and fatigue. These are study findings, not promised results for a catalogue product.
Where is it in clinical trials?
Eloralintide has completed Phase 1 and Phase 2 studies and is now in Phase 3 development. ENLIGHTEN-1 (NCT07321886) is enrolling adults with obesity or overweight without type 2 diabetes, with a target of 1,980 participants. Its main and extension phases are listed through July 2030; this is a study timeline, not an approval or launch date.
It remains investigational. This coming-soon listing does not mean it has regulatory approval or that these pen and vial formats are equivalent to Lilly’s clinical-trial material. No price or release date has been announced here.
Plain-English identity
What is Eloralintide?
The entry above identifies the compound or catalogue name. Published findings for a molecule do not establish the identity, effects or quality of this particular listed preparation.
Check the independent identity reference: Lilly: Eloralintide mechanism and clinical development ↗Third-party documentation
Certificates of Analysis
Reference reports concern the named submitted samples. A catalogue batch match has not been established; check the strength and source on each report.This should be treated as “not displayed”, not as evidence that analytical verification exists.
Browse all available COAsLast reviewed 28 October 2026. Research and reference information only. This page does not provide dosing instructions, treatment recommendations or medical advice. Not for human or veterinary consumption.